Patents by Inventor Marie-Paule Heitz Neidhart
Marie-Paule Heitz Neidhart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6339093Abstract: The present invention relates to compounds of the formula wherein R1 is hydrogen, lower alkyl, lower alkoxy, hydroxy, amino, nitro, cyano, lower alkyl-amino, di-lower alkyl-amino or halogen; R2 is hydrogen, lower alkyl, amino, pyrrolidin-3-ol, pyrrolidin-2-yl-methanol or —NHCH2CHROH; R3 is hydrogen or halogen; R is hydrogen, lower alkyl or —CH2OH; n is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof which are are NMDA(N-methyl-D-aspartate)-receptor subtype selective blockers.Type: GrantFiled: September 26, 2000Date of Patent: January 15, 2002Assignee: Hoffmann-la Roche Inc.Inventors: Alexander Alanine, Serge Burner, Bernd Buettelmann, Marie-Paule Heitz Neidhart, Georg Jaeschke, Emmanuel Pinard, René Wyler
-
Patent number: 6310213Abstract: The invention relates to compounds of the general formula wherein R1 signifies hydrogen or hydroxy; R2 signifies hydrogen or methyl; and X signifies —O— or —CH2— and their pharmaceutically acceptable acid addition salts. It has been shown that these compounds have a good affitity to the NMDA receptor and they are therefore useful in the treatment of diseases, wherein the therapeutic indications include acute forms of neurodegeneration caused, e.g., by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and, diseases such as schizophrenia, anxiety, depression and chronic/acute pain.Type: GrantFiled: June 2, 2000Date of Patent: October 30, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Alexander Alanine, Serge Burner, Bernd Büttelmann, Marie-Paule Heitz Neidhart, Georg Jaeschke, Emmanuel Pinard, René Wyler
-
Patent number: 6265426Abstract: The present invention relates to triazole and imidazole derivatives of formula I and to their pharmaceutically acceptable acid addition salts. These compounds are NMDA receptor subtype blockers and are useful for the treatment of diseases related to the NMDA receptor.Type: GrantFiled: July 19, 2000Date of Patent: July 24, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Alexander Alanine, Bernd Büttelmann, Marie-Paule Heitz Neidhart, Georg Jaeschke, Emmanuel Pinard, René Wyler
-
Patent number: 6184236Abstract: The present invention provides a method of treatment of a disease associated with neurodegeneration by administering a therapeutically effective amount of a compound of the general formula wherein Ar1 is phenyl, naphthyl or tetrahydronaphthyl, optionally substituted by hydroxy, lower alkoxy, nitro, amino or methanesulfonamide; Ar2 is phenyl, naphthyl or tetrahydronaphthyl, optionally substituted by lower alkyl or halogen; X is C, CH, C(OH) or N; Y is —CH2−, CH or O; Z —CH2—, —CH(CH3)— or —C(CH3)2—; R1 is hydrogen, lower alkyl or acetyl; A is C═O or —(CHR2)n—, wherein R2 is hydrogen, lower alkyl or hydroxy-lower alkyl; B is —(CH2)n—, O, —CH(OH)(CH2)n—, —CH(CH2OH)(CH2)n—, —(CH2)n CH(OH)— or —CH(CH2OH)—; - - - may be a bond; and n is 0-4, or pharmaceutically acceptable acid addition salts thereof.Type: GrantFiled: August 9, 1999Date of Patent: February 6, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Alexander Alanine, Bernd Büttelmann, Marie-Paule Heitz Neidhart, Emmanuel Pinard, René Wyler
-
Patent number: 6153624Abstract: The present invention relates to the use of pyrrolidine and piperidine derivatives of the general formula ##STR1## wherein R.sup.1 and R.sup.2 are, independently from each other, hydrogen, lower alkoxy, hydroxy, halogen, --CONH.sub.2 or --C(O)O-lower alkyl; or taken together are --O--CH.sub.2 O;R.sup.3 and R.sup.4 are, independently from each other, hydrogen, lower alkoxy, benzyloxy, halogen, hydroxy, --CONH.sub.2 or --SCH3; or taken together are --O--CH.sub.2 --O--;R.sup.5 is hydrogen or lower alkyl;X and Y are, independently from each other --CH(OH)--, --(CH.sub.2).sub.n --, --C(O)-- or --CH(lower alkoxy)-; andin, n and p are 1 or 2;and to their pharmaceutically acceptable addition salts for the treatment of diseases caused by over activation of NMDA receptor subtypes.Type: GrantFiled: July 28, 1999Date of Patent: November 28, 2000Assignee: Hoffman-LaRoche Inc.Inventors: Alexander Alanine, Bernd Buttelmann, Marie-Paule Heitz Neidhart, Emmanuel Pinard, Rene Wyler
-
Patent number: 6071929Abstract: The present invention relates to the use of tetrahydroisoquinoline derivatives of the general formula: ##STR1## wherein: A is arylR.sup.1 is hydrogen, hydroxy, lower alkyl, lower alkoxy, R--CO-- or R--COO--, wherein R is lower alkyl;R.sup.2 is hydrogen, lower alkyl or cycloalkylR.sup.3 -R.sup.7 are independently hydrogen, lower alkyl, lower alkoxy, hydroxy orR.sup.3 and R.sup.4 taken together are --(CH.sub.2).sub.n -- orR.sup.6 and R.sup.7 taken together are --OCH.sub.2 O-- andn is 3 or 4,as well as pharmaceutically acceptable salts for the manufacture of medicaments for the control or treatment of diseases which represent therapeutic indications for NMDA receptor subtype specific blockers.Type: GrantFiled: May 26, 1999Date of Patent: June 6, 2000Assignee: Hoffman-La Roche Inc.Inventors: Alexander Alanine, Anne Bourson, Bernd Buttelmann, Gunther Fischer, Marie-Paule Heitz Neidhart, Vincent Mutel, Emmanuel Pinard, Stephan Rover, Gerhard Trube, Rene Wyler
-
Patent number: 6015824Abstract: The present invention relates to the use of pyrrolidine and piperidine derivatives of the general formula ##STR1## wherein R.sup.1 and R.sup.2 are, independently from each other, hydrogen, lower alkoxy, hydroxy, halogen, --CONH.sub.2 or --C(O)O-lower alkyl; or taken together are --O--CH.sub.2 O;R.sup.3 and R.sup.4 are, independently from each other, hydrogen, lower alkoxy, benzyloxy, halogen, hydroxy, --CONH.sub.2 or --SCH.sub.3 ; or taken together are --O--CH.sub.2 --O--;Y is --CH(OH)--, --(CH.sub.2).sub.n --, --C(O)-- or --CH(lower alkoxy)--; andm, n and p are 1 or 2;and to their pharmaceutically acceptable addition salts for the treatment of diseases caused by over activation of NMDA receptor subtypes.Type: GrantFiled: January 20, 1999Date of Patent: January 18, 2000Assignee: Hoffmann-La Roche AGInventors: Alexander Alanine, Bernd Buttelmann, Marie-Paule Heitz Neidhart, Emmanuel Pinard, Rene Wyler
-
Patent number: 5962472Abstract: The present invention relates to the use of compounds of general formula ##STR1## wherein R.sup.1 is hydrogen, halogen, lower alkyl or lower alkoxy;R.sup.2 is hydrogen;R.sup.3 is hydrogen, amino, ureido, lower alkylcarbonyl, lower alkyl-sulfonylamino, lower alkylcarbamoyl, carbamoyl, lower alkyloxycarbamoyl, lower alkylamino orR.sup.2 and R.sup.3 taken together are --(CH.sub.2).sub.m --X is methylene, hydroxymethylene, lower alkoxymethylene or carbonyl,n is 0, 1 or 2 andm is 3 or 4as well as pharmaceutically acceptable salts for the control or treatment of diseases which represent therapeutic indications for NMDA receptor subtype specific blockers.Type: GrantFiled: March 7, 1997Date of Patent: October 5, 1999Assignee: Hoffmann-La Roche Inc.Inventors: Anne Bourson, Gunther Fischer, Marie-Paule Heitz Neidhart, Vincent Mutel, Gerhard Trube
-
Patent number: 5952344Abstract: The present invention relates to the use of tetrahydroisoquinoline derivatives of the general formula ##STR1## wherein A is arylR.sup.1 is hydrogen, hydroxy, lower alkyl, lower alkoxy, R--CO-- or R--COO--, wherein R is lower alkyl;R.sup.2 is hydrogen, lower alkyl or cycloalkylR.sup.3 -R.sup.7 are independently hydrogen, lower alkyl, lower alkoxy, hydroxy orR.sup.3 and R.sup.4 taken together are --(CH.sub.2).sub.n -- orR.sup.6 and R.sup.7 taken together are --OCH.sub.2 O-- andn is 3 or 4,as well as pharmaceutically acceptable salts for the manufacture of medicaments for the control or treatment of diseases which represent therapeutic indications for NMDA receptor subtype specific blockers.Type: GrantFiled: January 19, 1998Date of Patent: September 14, 1999Assignee: Hoffmann-La Roche Inc.Inventors: Alexander Alanine, Anne Bourson, Bernd Buttelmann, Gunther Fischer, Marie-Paule Heitz Neidhart, Vincent Mutel, Emmanuel Pinard, Stephan Rover, Gerhard Trube, Rene Wyler
-
Patent number: 5889026Abstract: The present invention relates to compounds of the formula ##STR1## wherein x is --O--, --NH--, --CH.sub.2 --, --CH.dbd., --CO.sub.2 --, --CONH--, --CON(lower alkyl)--, --S-- and --SO.sub.2 --;R.sup.1 -R.sup.4 are, independently from each other hydrogen, halogen, hydroxy, amino, nitro, lower-alkyl-sulfonylamido, 1- or 2-imidazolyl, 1-(1,2,4-triazolyl) or acetamido;R.sup.5, R.sup.6 are, independently from each other hydrogen, lower-alkyl, hydroxy, lower alkoxy or oxo;R.sup.7 -R.sup.10 are, independently from each other hydrogen, lower-alkyl, halogen, trifluoromethyl or lower-alkoxy;n is 0 or 1;and to pharmaceutically acceptable acid addition salts thereof. Compounds of the present invention are NMDA(N-methyl-D-aspartate)-receptor subtype selective blockers.Type: GrantFiled: July 14, 1997Date of Patent: March 30, 1999Assignee: Hoffmann-La Roche Inc.Inventors: Alexander Alanine, Bernd Buttelmann, Marie-Paule Heitz Neidhart, Emmanuel Pinard, Rene Wyler
-
Patent number: 5688803Abstract: Compounds of general formula (Ia), (Ib) and (II), wherein R.sup.1 and R.sup.2 each independently signify hydrogen, lower alkyl, lower alkoxy, nitro, trifluoromethyl, amino, halogen, cyano or R.sup.3 R.sup.4 NS(O).sub.2 -- and R.sup.3 and R.sup.4 signify lower alkyl, and R.sup.2 can additionally signify morpholino or thiomorpholino, a 5- or 6-membered heterocycle with 1-3N atoms optionally substituted by lower alkyl, hydroxy, amino or the group --CH.sub.2 NHCH.sub.3, a bicyclic heterocycle with 1-3N atoms or a group --NR.sup.5 R.sup.6 or --OR.sup.5 in which R.sup.5 and R.sup.6 can be the same or different and signify hydrogen, lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, amino-lower alkyl or lower alkylamino-lower alkyl, and X in formula (II) signifies --CH.dbd.CH--, --CH.dbd.N--, --NH--, --CO-- or --O--, as well as pharmaceutically usable salts of compounds of general formula (Ia), (Ib) and (II).Type: GrantFiled: November 15, 1996Date of Patent: November 18, 1997Assignee: Hoffmann-La Roche Inc.Inventors: Bernd Buttelmann, Thierry Godel, Laurence Gross, Marie-Paule Heitz Neidhart, Claus Riemer, Rene Wyler